[{"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-001", "question": "A 68-year-old man is 18 days post-Ivor Lewis esophagectomy with gastric conduit reconstruction for stage III esophageal adenocarcinoma. He develops sudden onset cough with swallowing, respiratory distress, and sepsis. Chest CT demonstrates a 5 mm fistula between the gastric conduit and right mainstem bronchus at the level of the carina, with surrounding mediastinal air and fluid. Bronchoscopy confirms the fistula with conduit mucosa visible. What is the definitive management?", "options": ["A) Endoscopic placement of overlapping esophageal and airway stents", "B) Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy", "C) NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks", "D) Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy", "E) Cervical esophagostomy and conduit abandonment without fistula repair"], "answer": "B", "answer_index": 1, "explanation": "Early postoperative tracheobronchial-gastric conduit fistula requires urgent surgical repair with viable muscle flap reinforcement; conduit ischemia at the anastomotic line necessitates conduit resection and delayed reconstruction. Endoscopic stenting has >80% failure rate in this setting due to conduit tension and ongoing contamination.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include sudden cough with swallowing, respiratory distress, sepsis, CT-confirmed 5 mm gastrobronchial fistula with mediastinal air and fluid, and bronchoscopic visualization of conduit mucosa, indicating an acute postoperative complication likely from anastomotic ischemia or leak requiring definitive intervention. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., timing 18 days post-op, sepsis, fistula location) to support B as uniquely best, with alternatives inferior due to high failure risks or inadequacy for sepsis/fistula repair. Main medical accuracy issue(s): none; aligns with current standards for early postoperative tracheobronchial-gastric conduit fistulas, where urgent surgical repair with muscle flap reinforcement and potential conduit resection is definitive, especially with suspected ischemia and sepsis; endoscopic stenting has documented high failure rates (>80%) in this setting per literature, while conservative management risks ongoing contamination. Minimal fix: none needed, as the item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include sudden cough with swallowing, respiratory distress, sepsis, CT-confirmed 5 mm gastrobronchial fistula with mediastinal air and fluid, and bronchoscopic visualization of conduit mucosa, indicating an acute postoperative complication likely from anastomotic ischemia or leak requiring definitive intervention. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., timing 18 days post-op, sepsis, fistula location) to support B as uniquely best, with alternatives inferior due to high failure risks or inadequacy for sepsis/fistula repair. Main medical accuracy issue(s): none; aligns with current standards for early postoperative tracheobronchial-gastric conduit fistulas, where urgent surgical repair with muscle flap reinforcement and potential conduit resection is definitive, especially with suspected ischemia and sepsis; endoscopic stenting has documented high failure rates (>80%) in this setting per literature, while conservative management risks ongoing contamination. Minimal fix: none needed, as the item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-002", "question": "A 54-year-old woman with antiphospholipid syndrome presents with 12 hours of severe epigastric pain and vomiting. CT angiography demonstrates thrombosis of the superior mesenteric vein extending into the intrahepatic portal veins, bowel wall thickening with pneumatosis of the proximal jejunum, and ascites. Exploratory laparotomy reveals dusky but viable small bowel without frank necrosis. What is the most appropriate next step?", "options": ["A) Resection of all affected bowel and mesenteric venous thrombectomy", "B) Systemic unfractionated heparin infusion targeting aPTT 2-3x control", "C) Catheter-directed thrombolysis of the superior mesenteric vein with alteplase via transhepatic approach", "D) Therapeutic enoxaparin 1 mg/kg twice daily and second-look laparotomy in 24 hours", "E) Mesenteric venous stent placement across the thrombosed segment"], "answer": "C", "answer_index": 2, "explanation": "In acute mesenteric venous thrombosis with bowel ischemia but viable intestine, catheter-directed thrombolysis restores venous outflow and prevents progression to infarction. Systemic anticoagulation alone is insufficient for extensive thrombus; surgical thrombectomy is ineffective and causes major bleeding.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. The clinical problem is determining the next management step for acute mesenteric venous thrombosis (MVT) with ischemic signs but viable bowel in a hypercoagulable patient. Key stem clues: antiphospholipid syndrome (prothrombotic), 12-hour severe pain/vomiting, CT showing extensive SMV-to-portal vein thrombosis, jejunal pneumatosis/bowel thickening/ascites (ischemia), laparotomy confirming dusky but viable bowel without necrosis. These imply need for urgent venous outflow restoration/anticoagulation to prevent infarction. Keyed C (catheter-directed thrombolysis) fits for rapid recanalization in extensive acute MVT with ischemia, assuming high progression risk, but requires post-op bleeding risk assumption. Alternatives: A worse due to unnecessary resection/thrombectomy risks; B (systemic heparin) defensible as standard initial therapy; D (enoxaparin + second-look) equally defensible for anticoagulation with monitoring post-lap; E inferior as stenting not standard for venous thrombosis. Main logical issue: Stem underspecified on ongoing ischemia severity or anticoagulation response, allowing B, C, D as near-equally reasonable next steps under varying guideline interpretations, leading to multiple defensible answers. Main medical accuracy issues: Keyed C overstates thrombolysis as first-line; per ACG/UpToDate, systemic anticoagulation is mainstay for acute MVT without necrosis, with thrombolysis reserved for refractory/extensive cases or deterioration—rationale inaccurately deems systemic AC insufficient. Minimal fix: Add stem detail 'despite initial heparin, symptoms worsen' to make C uniquely best, and rekey accordingly.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. The clinical problem is determining the next management step for acute mesenteric venous thrombosis (MVT) with ischemic signs but viable bowel in a hypercoagulable patient. Key stem clues: antiphospholipid syndrome (prothrombotic), 12-hour severe pain/vomiting, CT showing extensive SMV-to-portal vein thrombosis, jejunal pneumatosis/bowel thickening/ascites (ischemia), laparotomy confirming dusky but viable bowel without necrosis. These imply need for urgent venous outflow restoration/anticoagulation to prevent infarction. Keyed C (catheter-directed thrombolysis) fits for rapid recanalization in extensive acute MVT with ischemia, assuming high progression risk, but requires post-op bleeding risk assumption. Alternatives: A worse due to unnecessary resection/thrombectomy risks; B (systemic heparin) defensible as standard initial therapy; D (enoxaparin + second-look) equally defensible for anticoagulation with monitoring post-lap; E inferior as stenting not standard for venous thrombosis. Main logical issue: Stem underspecified on ongoing ischemia severity or anticoagulation response, allowing B, C, D as near-equally reasonable next steps under varying guideline interpretations, leading to multiple defensible answers. Main medical accuracy issues: Keyed C overstates thrombolysis as first-line; per ACG/UpToDate, systemic anticoagulation is mainstay for acute MVT without necrosis, with thrombolysis reserved for refractory/extensive cases or deterioration—rationale inaccurately deems systemic AC insufficient. Minimal fix: Add stem detail 'despite initial heparin, symptoms worsen' to make C uniquely best, and rekey accordingly.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-003", "question": "A 42-year-old man with MEN1 syndrome (germline MEN1 c.628_631del) is found to have a 2.8 cm duodenal gastrinoma with 3 regional periduodenal lymph node metastases on Ga-68 DOTATATE PET/CT. Serum gastrin is 2,200 pg/mL with gastric pH <2. He has no pancreatic lesions. What is the optimal surgical management?", "options": ["A) Whipple pancreaticoduodenectomy with pylorus preservation", "B) Pancreas-preserving duodenectomy with regional lymphadenectomy", "C) Endoscopic submucosal dissection of the duodenal tumor", "D) Long-acting octreotide 30 mg monthly without surgery", "E) Tumor enucleation through duodenotomy only"], "answer": "B", "answer_index": 1, "explanation": "For large duodenal neuroendocrine tumors in MEN1, pancreas-preserving duodenectomy achieves oncologic clearance while preserving pancreatic function, which is critical as these patients inevitably develop pancreatic neuroendocrine tumors requiring future pancreatic surgery. Whipple procedure is excessively morbid for duodenal disease alone.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include MEN1 syndrome with germline mutation, a 2.8 cm duodenal gastrinoma with 3 regional lymph node metastases on Ga-68 DOTATATE PET/CT, elevated serum gastrin (2,200 pg/mL) and gastric pH <2, and absence of pancreatic lesions. These support surgical resection for oncologic clearance while preserving pancreatic function, critical in MEN1 due to high risk of future pancreatic neuroendocrine tumors. The keyed answer B (pancreas-preserving duodenectomy with regional lymphadenectomy) fits by addressing the tumor and nodes without pancreatic resection, avoiding unnecessary morbidity. Main logical issues: None; the stem provides sufficient details for discriminating a single best option without contradictions or underspecification, as size and metastases preclude non-surgical or minimal approaches. Alternatives are inferior: A is overly morbid (removes pancreatic head); C is unsuitable for large tumor with metastases; D avoids surgery despite resectable disease; E fails to address lymph nodes. Main medical accuracy issues: None; aligns with current guidelines for MEN1-associated duodenal gastrinomas, emphasizing pancreas preservation to facilitate future interventions. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include MEN1 syndrome with germline mutation, a 2.8 cm duodenal gastrinoma with 3 regional lymph node metastases on Ga-68 DOTATATE PET/CT, elevated serum gastrin (2,200 pg/mL) and gastric pH <2, and absence of pancreatic lesions. These support surgical resection for oncologic clearance while preserving pancreatic function, critical in MEN1 due to high risk of future pancreatic neuroendocrine tumors. The keyed answer B (pancreas-preserving duodenectomy with regional lymphadenectomy) fits by addressing the tumor and nodes without pancreatic resection, avoiding unnecessary morbidity. Main logical issues: None; the stem provides sufficient details for discriminating a single best option without contradictions or underspecification, as size and metastases preclude non-surgical or minimal approaches. Alternatives are inferior: A is overly morbid (removes pancreatic head); C is unsuitable for large tumor with metastases; D avoids surgery despite resectable disease; E fails to address lymph nodes. Main medical accuracy issues: None; aligns with current guidelines for MEN1-associated duodenal gastrinomas, emphasizing pancreas preservation to facilitate future interventions. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include post-FOLFOX timing, painful hepatomegaly, ascites, jaundice, elevated bilirubin/ALT/INR, and biopsy findings of sinusoidal congestion with zone 3 necrosis without portal inflammation, classic for sinusoidal obstruction syndrome (SOS/VOD) from oxaliplatin. These discriminate toward defibrotide as definitive therapy, aligning with guidelines for severe SOS. Main logical issue(s): None; stem provides sufficient details for unique selection without contradictions or underspecification. Main medical accuracy issue(s): None; defibrotide is FDA-approved and standard for severe SOS post-chemotherapy, restoring endothelial function; rationale correctly notes TIPS contraindication due to diffuse injury, steroids' ineffectiveness, and transplant's role only in fulminant cases with encephalopathy (absent here). Alternatives are appropriately inferior: A lacks evidence, C risks complications in SOS, D suits acetaminophen toxicity, E premature without failure signs. The item is clinically realistic and board-relevant. Minimal fix: None needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include post-FOLFOX timing, painful hepatomegaly, ascites, jaundice, elevated bilirubin/ALT/INR, and biopsy findings of sinusoidal congestion with zone 3 necrosis without portal inflammation, classic for sinusoidal obstruction syndrome (SOS/VOD) from oxaliplatin. These discriminate toward defibrotide as definitive therapy, aligning with guidelines for severe SOS. Main logical issue(s): None; stem provides sufficient details for unique selection without contradictions or underspecification. Main medical accuracy issue(s): None; defibrotide is FDA-approved and standard for severe SOS post-chemotherapy, restoring endothelial function; rationale correctly notes TIPS contraindication due to diffuse injury, steroids' ineffectiveness, and transplant's role only in fulminant cases with encephalopathy (absent here). Alternatives are appropriately inferior: A lacks evidence, C risks complications in SOS, D suits acetaminophen toxicity, E premature without failure signs. The item is clinically realistic and board-relevant. Minimal fix: None needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-005", "question": "A 35-year-old woman with CFH p.Arg1215Gln mutation undergoes deceased donor kidney transplantation. On postoperative day 7, she develops rising creatinine (3.4 mg/dL), thrombocytopenia (45,000/μL), schistocytes, and hemolysis. Eculizumab 900 mg weekly was started preemptively on day 0. Platelets normalize by day 10 but creatinine continues to rise to 4.8 mg/dL. What is the next step?", "options": ["A) Increase eculizumab dose to 1,200 mg weekly", "B) Initiate daily plasma exchange with fresh frozen plasma", "C) Switch to ravulizumab 3,600 mg maintenance dose", "D) Measure eculizumab trough level and CH50 activity", "E) Proceed with transplant nephrectomy"], "answer": "D", "answer_index": 3, "explanation": "Breakthrough atypical HUS despite eculizumab requires therapeutic drug monitoring to distinguish underdosing from complement amplification via properdin or C5 gain-of-function mutation. Pharmacokinetic assessment guides therapy rather than empiric dose escalation or ineffective plasma exchange.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: CFH p.Arg1215Gln mutation (predisposing to aHUS), deceased donor kidney transplant, POD7 TMA features (rising Cr to 3.4 mg/dL, thrombocytopenia 45,000/μL, schistocytes, hemolysis), preemptive eculizumab 900 mg weekly from day 0, platelets normalize by day 10 but Cr rises to 4.8 mg/dL. These imply breakthrough aHUS despite therapy, necessitating evaluation of drug efficacy before escalation. Main logical issue(s), if any: None; stem provides sufficient details for discriminating a single best next step without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., KDIGO) for aHUS management in transplant recipients, where therapeutic drug monitoring (eculizumab trough and CH50) is recommended for breakthrough TMA to rule out underdosing before dose adjustment or alternative therapies. The rationale correctly notes distinction from complement amplification causes. Item is clinically realistic and board-relevant. Minimal fix: N/A; item is already unambiguous and accurate, though adding 'suspected antibody-mediated rejection ruled out' could enhance specificity if desired.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: CFH p.Arg1215Gln mutation (predisposing to aHUS), deceased donor kidney transplant, POD7 TMA features (rising Cr to 3.4 mg/dL, thrombocytopenia 45,000/μL, schistocytes, hemolysis), preemptive eculizumab 900 mg weekly from day 0, platelets normalize by day 10 but Cr rises to 4.8 mg/dL. These imply breakthrough aHUS despite therapy, necessitating evaluation of drug efficacy before escalation. Main logical issue(s), if any: None; stem provides sufficient details for discriminating a single best next step without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., KDIGO) for aHUS management in transplant recipients, where therapeutic drug monitoring (eculizumab trough and CH50) is recommended for breakthrough TMA to rule out underdosing before dose adjustment or alternative therapies. The rationale correctly notes distinction from complement amplification causes. Item is clinically realistic and board-relevant. Minimal fix: N/A; item is already unambiguous and accurate, though adding 'suspected antibody-mediated rejection ruled out' could enhance specificity if desired.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-006", "question": "A 28-year-old man is day +45 after matched unrelated donor allogeneic stem cell transplant for AML in CR1. He develops new hypertension (BP 165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, and thrombocytopenia. ADAMTS13 activity is 45%. Tacrolimus was stopped 14 days ago for rising creatinine. What is the appropriate therapy?", "options": ["A) Eculizumab 900 mg weekly IV", "B) High-dose methylprednisolone 1 g IV x3 days plus plasma exchange", "C) Rituximab 375 mg/m2 weekly for 4 doses", "D) Resume tacrolimus and target level 8-10 ng/mL", "E) Supportive care with aggressive blood pressure control only"], "answer": "A", "answer_index": 0, "explanation": "Transplant-associated thrombotic microangiopathy is mediated by complement activation independent of ADAMTS13; eculizumab blocks terminal complement and is the only effective therapy. Plasma exchange is ineffective; resuming calcineurin inhibitors worsens TMA.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Post-allogeneic SCT day +45, new hypertension (165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, thrombocytopenia, ADAMTS13 activity 45% (rules out TTP, as <10% required), tacrolimus stopped 14 days ago for rising creatinine. These point to transplant-associated thrombotic microangiopathy (TA-TMA), often complement-mediated and independent of ADAMTS13 deficiency. Main logical issue(s): None; stem provides sufficient discriminating findings (e.g., ADAMTS13 level distinguishes from TTP, recent tacrolimus cessation avoids confounding) to support eculizumab as unique best therapy over alternatives like resuming tacrolimus (worsens TMA) or plasma exchange (ineffective for TA-TMA). Main medical accuracy issue(s): Consistent with current standards; eculizumab targets terminal complement in TA-TMA, per guidelines (e.g., ASH, EBMT); rationale accurately notes PEX inefficacy and CNI risks, though real-world use may include supportive care first—item frames as 'appropriate therapy' implying targeted intervention. Minimal fix: None needed; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Post-allogeneic SCT day +45, new hypertension (165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, thrombocytopenia, ADAMTS13 activity 45% (rules out TTP, as <10% required), tacrolimus stopped 14 days ago for rising creatinine. These point to transplant-associated thrombotic microangiopathy (TA-TMA), often complement-mediated and independent of ADAMTS13 deficiency. Main logical issue(s): None; stem provides sufficient discriminating findings (e.g., ADAMTS13 level distinguishes from TTP, recent tacrolimus cessation avoids confounding) to support eculizumab as unique best therapy over alternatives like resuming tacrolimus (worsens TMA) or plasma exchange (ineffective for TA-TMA). Main medical accuracy issue(s): Consistent with current standards; eculizumab targets terminal complement in TA-TMA, per guidelines (e.g., ASH, EBMT); rationale accurately notes PEX inefficacy and CNI risks, though real-world use may include supportive care first—item frames as 'appropriate therapy' implying targeted intervention. Minimal fix: None needed; item is unambiguous and accurate as is.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-007", "question": "A 14-year-old girl with chronic atypical neutrophilic dermatosis, lipodystrophy, and recurrent fevers (CANDLE syndrome) has persistent inflammatory lesions and fevers despite anakinra 100 mg daily and canakinumab 150 mg monthly. Genetic testing confirms PSMB8 c.224C>T mutation. What is the next therapy?", "options": ["A) High-dose prednisone 1 mg/kg/day", "B) Baricitinib 4 mg daily (JAK1/2 inhibitor)", "C) Tocilizumab 8 mg/kg IV monthly", "D) Thalidomide 100 mg nightly", "E) Allogeneic stem cell transplant"], "answer": "B", "answer_index": 1, "explanation": "CANDLE syndrome is a type I interferonopathy due to proteasome dysfunction; JAK inhibitors block downstream interferon signaling and are effective when IL-1 blockade fails. Baricitinib has shown efficacy in refractory cases. Anti-IL-6 and thalidomide are ineffective; transplant is experimental.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 14-year-old girl with CANDLE syndrome (chronic atypical neutrophilic dermatosis, lipodystrophy, recurrent fevers), persistent inflammatory lesions and fevers despite IL-1 blockade with anakinra and canakinumab, confirmed PSMB8 c.224C>T mutation implying proteasome dysfunction and type I interferonopathy. These clues point to need for therapy targeting interferon signaling after IL-1 failure. Main logical issue(s), if any: None; stem is internally consistent, supports baricitinib as unique best next step without requiring unstated assumptions, with alternatives clearly inferior based on vignette. Main medical accuracy issue(s), if any: None; aligns with current understanding of CANDLE as interferonopathy where JAK inhibitors like baricitinib are effective in refractory cases per case reports and guidelines; IL-1 blockers may fail, anti-IL-6 (tocilizumab) and thalidomide lack efficacy, transplant is experimental/not first-line. Item's logic is precise, reflecting modern autoinflammatory disease management. Minimal fix: None required, as item is already unambiguous and accurate; optionally, add 'refractory to IL-1 inhibition' explicitly in stem for emphasis, though not necessary.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 14-year-old girl with CANDLE syndrome (chronic atypical neutrophilic dermatosis, lipodystrophy, recurrent fevers), persistent inflammatory lesions and fevers despite IL-1 blockade with anakinra and canakinumab, confirmed PSMB8 c.224C>T mutation implying proteasome dysfunction and type I interferonopathy. These clues point to need for therapy targeting interferon signaling after IL-1 failure. Main logical issue(s), if any: None; stem is internally consistent, supports baricitinib as unique best next step without requiring unstated assumptions, with alternatives clearly inferior based on vignette. Main medical accuracy issue(s), if any: None; aligns with current understanding of CANDLE as interferonopathy where JAK inhibitors like baricitinib are effective in refractory cases per case reports and guidelines; IL-1 blockers may fail, anti-IL-6 (tocilizumab) and thalidomide lack efficacy, transplant is experimental/not first-line. Item's logic is precise, reflecting modern autoinflammatory disease management. Minimal fix: None required, as item is already unambiguous and accurate; optionally, add 'refractory to IL-1 inhibition' explicitly in stem for emphasis, though not necessary.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-008", "question": "A 38-year-old man from Vietnam with chronic mucocutaneous candidiasis is found to have STAT1 gain-of-function c.821T>C mutation. He presents with disseminated umbilicated papular skin lesions, hepatosplenomegaly, and fevers. Skin biopsy shows intracellular yeast forms with central septation. What is optimal therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone for 14 days", "B) Voriconazole 6 mg/kg IV q12h then 4 mg/kg maintenance", "C) Liposomal amphotericin B induction then itraconazole maintenance plus ruxolitinib 10 mg BID", "D) Caspofungin 70 mg loading then 50 mg daily", "E) Fluconazole 800 mg loading then 400 mg daily"], "answer": "C", "answer_index": 2, "explanation": "STAT1 GOF causes defective Th17 immunity leading to refractory dimorphic fungal infections. Talaromyces marneffei requires initial amphotericin induction followed by itraconazole maintenance. Adding JAK inhibition (ruxolitinib) reverses the underlying immunodeficiency and is essential for cure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include patient's origin from Vietnam (endemic for Talaromyces marneffei), STAT1 gain-of-function mutation causing defective Th17 immunity and refractory fungal infections, disseminated umbilicated papular lesions, hepatosplenomegaly, fevers, and biopsy showing intracellular yeast with central septation (characteristic of T. marneffei). These point to disseminated penicilliosis requiring amphotericin B induction followed by itraconazole maintenance, with ruxolitinib addressing the underlying STAT1 hyperactivity for better control. Main logical issues: none; stem provides sufficient discriminating details for single best choice without contradictions or underspecification. Main medical accuracy issues: none; aligns with IDSA guidelines for T. marneffei treatment (amphotericin induction then itraconazole) and emerging evidence for JAK inhibitors like ruxolitinib in STAT1 GOF for refractory cases, consistent with current standards. Minimal fix: none needed, as item is unambiguous and accurate. The clinical problem asks for optimal therapy in this immunocompromised patient with likely disseminated T. marneffei. Alternatives are inferior: A lacks maintenance; B uses voriconazole (not preferred); D employs caspofungin (ineffective against dimorphics); E uses fluconazole (poor activity).\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include patient's origin from Vietnam (endemic for Talaromyces marneffei), STAT1 gain-of-function mutation causing defective Th17 immunity and refractory fungal infections, disseminated umbilicated papular lesions, hepatosplenomegaly, fevers, and biopsy showing intracellular yeast with central septation (characteristic of T. marneffei). These point to disseminated penicilliosis requiring amphotericin B induction followed by itraconazole maintenance, with ruxolitinib addressing the underlying STAT1 hyperactivity for better control. Main logical issues: none; stem provides sufficient discriminating details for single best choice without contradictions or underspecification. Main medical accuracy issues: none; aligns with IDSA guidelines for T. marneffei treatment (amphotericin induction then itraconazole) and emerging evidence for JAK inhibitors like ruxolitinib in STAT1 GOF for refractory cases, consistent with current standards. Minimal fix: none needed, as item is unambiguous and accurate. The clinical problem asks for optimal therapy in this immunocompromised patient with likely disseminated T. marneffei. Alternatives are inferior: A lacks maintenance; B uses voriconazole (not preferred); D employs caspofungin (ineffective against dimorphics); E uses fluconazole (poor activity).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-009", "question": "A 65-year-old man with metastatic melanoma on ipilimumab 3 mg/kg plus nivolumab 1 mg/kg presents with severe fatigue, hypotension (BP 85/50 mmHg), hyponatremia (Na 122 mEq/L), and headache. Troponin I is 15 ng/mL with normal EF 55%. Brain MRI shows diffuse pituitary enlargement with homogeneous enhancement. What is immediate management?", "options": ["A) Methylprednisolone 1 mg/kg/day IV alone", "B) Methylprednisolone 1 mg/kg/day plus infliximab 5 mg/kg", "C) Methylprednisolone 1 mg/kg/day plus mycophenolate mofetil 1 g BID", "D) Methylprednisolone 1 g IV x3 days plus anti-thymocyte globulin", "E) Hold immunotherapy and initiate supportive care only"], "answer": "C", "answer_index": 2, "explanation": "Combined hypophysitis and myocarditis from dual checkpoint inhibition requires high-dose steroids. Mycophenolate mofetil is preferred for steroid-refractory myocarditis as infliximab can worsen myocardial inflammation. Anti-thymocyte globulin is overly immunosuppressive in this setting.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 65-year-old with metastatic melanoma on ipilimumab plus nivolumab, presenting with severe fatigue, hypotension (85/50 mmHg), hyponatremia (122 mEq/L), headache, elevated troponin I (15 ng/mL) with normal EF (55%), and brain MRI showing diffuse pituitary enlargement—indicating immune-related hypophysitis and myocarditis with hemodynamic instability. These clues (hemodynamic compromise, combined irAEs from dual checkpoint inhibition) support immediate high-dose steroids plus additional immunosuppression for unstable myocarditis per ASCO guidelines. Main logical issue(s), if any: None; stem provides sufficient details for discriminating a single best option without contradictions or underspecification, as instability justifies adding mycophenolate immediately over steroids alone. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., ASCO 2021) recommending methylprednisolone 1-2 mg/kg plus mycophenolate for clinically unstable IO-myocarditis, preferring it over infliximab due to potential worsening of myocardial inflammation and over ATG due to excessive immunosuppression. Minimal fix: No fix required; item is already unambiguous and accurate, though optionally increase steroid dose in option C to 2 mg/kg for enhanced precision with guideline nuance.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 65-year-old with metastatic melanoma on ipilimumab plus nivolumab, presenting with severe fatigue, hypotension (85/50 mmHg), hyponatremia (122 mEq/L), headache, elevated troponin I (15 ng/mL) with normal EF (55%), and brain MRI showing diffuse pituitary enlargement—indicating immune-related hypophysitis and myocarditis with hemodynamic instability. These clues (hemodynamic compromise, combined irAEs from dual checkpoint inhibition) support immediate high-dose steroids plus additional immunosuppression for unstable myocarditis per ASCO guidelines. Main logical issue(s), if any: None; stem provides sufficient details for discriminating a single best option without contradictions or underspecification, as instability justifies adding mycophenolate immediately over steroids alone. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., ASCO 2021) recommending methylprednisolone 1-2 mg/kg plus mycophenolate for clinically unstable IO-myocarditis, preferring it over infliximab due to potential worsening of myocardial inflammation and over ATG due to excessive immunosuppression. Minimal fix: No fix required; item is already unambiguous and accurate, though optionally increase steroid dose in option C to 2 mg/kg for enhanced precision with guideline nuance.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-010", "question": "A 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, and baseline serum tryptase of 35 ng/mL is found to have heterozygous TPSAB1 copy number gain (α-tryptasemia). Symptoms persist despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. What is next therapy?", "options": ["A) Increase omalizumab to 600 mg monthly", "B) Prophylactic prednisone 10 mg daily", "C) Cromolyn sodium 200 mg QID", "D) Ketotifen 2 mg BID (mast cell stabilizer)", "E) Allergen immunotherapy based on skin testing"], "answer": "D", "answer_index": 3, "explanation": "Hereditary Alpha-Tryptasemia Syndrome causes constitutive mast cell activation; ketotifen stabilizes mast cell membranes and is effective when antihistamines fail. Omalizumab has variable efficacy; cromolyn is poorly absorbed systemically. Steroids are not prophylactic therapy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, baseline tryptase 35 ng/mL, heterozygous TPSAB1 copy number gain (α-tryptasemia), symptoms persisting despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. These point to hereditary alpha-tryptasemia (HαT) with refractory mast cell activation symptoms, implying need for additional mast cell stabilization. Keyed answer D (ketotifen) fits as a systemic mast cell stabilizer effective in HαT/MCAS when antihistamines and omalizumab fail. Alternatives: A worse due to variable omalizumab efficacy in HαT and 300 mg already trialed; B incorrect as prophylactic steroids not standard for long-term use; C suboptimal for systemic symptoms given poor oral absorption; E irrelevant for idiopathic/non-allergic mechanism. No main logical issues; stem allows discrimination of single best option without contradictions or underspecification. Main medical accuracy issues: Minor - rationale slightly overstates 'constitutive mast cell activation' (HαT involves elevated tryptase facilitating activation, not necessarily constitutive); otherwise aligns with consensus on symptomatic HαT management (antihistamines, stabilizers, biologics). Minimal fix: None required; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, baseline tryptase 35 ng/mL, heterozygous TPSAB1 copy number gain (α-tryptasemia), symptoms persisting despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. These point to hereditary alpha-tryptasemia (HαT) with refractory mast cell activation symptoms, implying need for additional mast cell stabilization. Keyed answer D (ketotifen) fits as a systemic mast cell stabilizer effective in HαT/MCAS when antihistamines and omalizumab fail. Alternatives: A worse due to variable omalizumab efficacy in HαT and 300 mg already trialed; B incorrect as prophylactic steroids not standard for long-term use; C suboptimal for systemic symptoms given poor oral absorption; E irrelevant for idiopathic/non-allergic mechanism. No main logical issues; stem allows discrimination of single best option without contradictions or underspecification. Main medical accuracy issues: Minor - rationale slightly overstates 'constitutive mast cell activation' (HαT involves elevated tryptase facilitating activation, not necessarily constitutive); otherwise aligns with consensus on symptomatic HαT management (antihistamines, stabilizers, biologics). Minimal fix: None required; item is unambiguous and accurate as is.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-011", "question": "A 57-year-old man is 6 hours status post bilateral sequential lung transplantation for idiopathic pulmonary fibrosis. He remains on 100% FiO2 with PaO2/FiO2 ratio of 85 despite inhaled nitric oxide at 40 ppm and optimal ventilator settings. Chest X-ray shows diffuse bilateral infiltrates. What is the optimal mechanical support strategy?", "options": ["A) Veno-venous ECMO via femoral-jugular cannulation", "B) Veno-arterial ECMO via central cannulation", "C) Extracorporeal CO2 removal with 1 L/min blood flow", "D) Inhaled epoprostenol 50 ng/kg/min only", "E) Veno-venous ECMO via dual-lumen cannula (Avalon) in right internal jugular vein"], "answer": "E", "answer_index": 4, "explanation": "Severe primary graft dysfunction grade 3 requires full respiratory support. Dual-lumen single-site VV-ECMO (Avalon) allows early mobilization and rehabilitation, which improves long-term outcomes. Femoral-jugular configuration limits mobility; VA-ECMO is unnecessary without cardiac failure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 57-year-old man 6 hours post-bilateral lung transplant for idiopathic pulmonary fibrosis, with PaO2/FiO2 ratio of 85 on 100% FiO2 despite inhaled nitric oxide and optimal ventilation, plus diffuse bilateral infiltrates on chest X-ray, indicating severe primary graft dysfunction (PGD) grade 3 with isolated refractory hypoxemia and no mention of cardiac failure. These clues point to the need for full extracorporeal respiratory support prioritizing mobility for rehabilitation. Main logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions, underspecification, or multiple defensible answers, supporting E as uniquely best due to single-site access enabling early mobilization, unlike A (limits mobility) or B (unnecessary for non-cardiac failure). Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., ISHLT) for VV-ECMO in severe PGD post-lung transplant, emphasizing dual-lumen cannulas for improved outcomes via mobility; ECCO2R is inadequate for hypoxemia, epoprostenol is adjunctive, and VA-ECMO reserved for hemodynamic instability. Minimal fix: No edit needed, but adding 'hemodynamically stable' to stem would further emphasize isolation of respiratory failure and preclude B more explicitly.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 57-year-old man 6 hours post-bilateral lung transplant for idiopathic pulmonary fibrosis, with PaO2/FiO2 ratio of 85 on 100% FiO2 despite inhaled nitric oxide and optimal ventilation, plus diffuse bilateral infiltrates on chest X-ray, indicating severe primary graft dysfunction (PGD) grade 3 with isolated refractory hypoxemia and no mention of cardiac failure. These clues point to the need for full extracorporeal respiratory support prioritizing mobility for rehabilitation. Main logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions, underspecification, or multiple defensible answers, supporting E as uniquely best due to single-site access enabling early mobilization, unlike A (limits mobility) or B (unnecessary for non-cardiac failure). Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., ISHLT) for VV-ECMO in severe PGD post-lung transplant, emphasizing dual-lumen cannulas for improved outcomes via mobility; ECCO2R is inadequate for hypoxemia, epoprostenol is adjunctive, and VA-ECMO reserved for hemodynamic instability. Minimal fix: No edit needed, but adding 'hemodynamically stable' to stem would further emphasize isolation of respiratory failure and preclude B more explicitly.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-012", "question": "A 72-year-old man has a 5.5 cm infrarenal abdominal aortic aneurysm with a thick circumferential rind of periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, and elevated ESR (85 mm/hr) and CRP (120 mg/L). What is the optimal management sequence?", "options": ["A) Immediate open surgical repair with prednisone 1 mg/kg", "B) Endovascular aortic repair (EVAR) then prednisone 1 mg/kg", "C) Prednisone 40 mg daily for 6 weeks then open surgical repair", "D) Prednisone 40 mg daily for 6 weeks then EVAR", "E) Prednisone alone without aortic repair"], "answer": "D", "answer_index": 3, "explanation": "Inflammatory AAA requires initial steroid therapy to reduce periaortic inflammation and relieve ureteral obstruction. Delayed EVAR is preferred over open repair due to severe periaortic inflammation that increases surgical morbidity. Steroids alone risk aneurysm rupture.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 72-year-old man with 5.5 cm infrarenal AAA, thick periaortic inflammatory rind, bilateral ureteral obstruction with hydronephrosis, and markedly elevated ESR (85 mm/hr) and CRP (120 mg/L), driving diagnosis of inflammatory AAA requiring inflammation reduction before repair to minimize morbidity and address obstruction. These findings imply need for initial corticosteroid therapy followed by aneurysm repair, with EVAR preferred over open surgery due to periaortic inflammation increasing open repair risks. Main logical issue(s): None; stem provides sufficient details for discriminating a unique best answer without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., SVS) for inflammatory AAA management—preoperative steroids (typically 0.5-1 mg/kg prednisone tapered over weeks) to reduce fibrosis and relieve ureteral obstruction, followed by delayed EVAR if anatomically suitable, as open repair in active inflammation heightens complications like adhesions and infection; 5.5 cm size warrants repair to prevent rupture, and steroids alone are insufficient. Minimal fix: Not needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 72-year-old man with 5.5 cm infrarenal AAA, thick periaortic inflammatory rind, bilateral ureteral obstruction with hydronephrosis, and markedly elevated ESR (85 mm/hr) and CRP (120 mg/L), driving diagnosis of inflammatory AAA requiring inflammation reduction before repair to minimize morbidity and address obstruction. These findings imply need for initial corticosteroid therapy followed by aneurysm repair, with EVAR preferred over open surgery due to periaortic inflammation increasing open repair risks. Main logical issue(s): None; stem provides sufficient details for discriminating a unique best answer without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., SVS) for inflammatory AAA management—preoperative steroids (typically 0.5-1 mg/kg prednisone tapered over weeks) to reduce fibrosis and relieve ureteral obstruction, followed by delayed EVAR if anatomically suitable, as open repair in active inflammation heightens complications like adhesions and infection; 5.5 cm size warrants repair to prevent rupture, and steroids alone are insufficient. Minimal fix: Not needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-013", "question": "A 58-year-old woman presents with a 4 cm pancreatic tail tumor, necrolytic migratory erythema, weight loss of 30 lbs, and new-onset diabetes. Biopsy confirms glucagonoma with Ki-67 8% and diffuse hepatic metastases on MRI. Serum glucagon is 2,500 pg/mL. What is first-line therapy?", "options": ["A) Distal pancreatectomy with splenectomy", "B) Octreotide LAR 30 mg intramuscular monthly", "C) Lanreotide autogel 120 mg deep subcutaneous every 4 weeks", "D) Everolimus 10 mg daily plus octreotide LAR", "E) Streptozocin 500 mg/m2 plus doxorubicin 50 mg/m2 every 3 weeks"], "answer": "C", "answer_index": 2, "explanation": "For metastatic glucagonoma, long-acting somatostatin analogs control hormone symptoms and have antiproliferative activity. Lanreotide 120 mg every 4 weeks is preferred over octreotide LAR due to consistent dosing. Everolimus is second-line; chemotherapy is reserved for progressive disease.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict: Not uniquely determinable. Key stem clues: 58-year-old woman with 4 cm pancreatic tail tumor, necrolytic migratory erythema, 30 lb weight loss, new-onset diabetes, biopsy-confirmed glucagonoma (Ki-67 8%), diffuse hepatic metastases, serum glucagon 2,500 pg/mL—indicating symptomatic metastatic well-differentiated pancreatic neuroendocrine tumor (glucagonoma). These drive first-line therapy as somatostatin analogs (SSAs) for symptom control and antiproliferative effects per NCCN/ENETS guidelines, ruling out surgery (A) due to metastases, everolimus combo (D) as second-line, and chemotherapy (E) for progression. Main logical issue: Stem supports SSAs but lacks discriminating details (e.g., administration preference) to choose uniquely between equivalent options B (octreotide LAR) and C (lanreotide); both are defensible first-line SSAs, leading to multiple answers (M) from underspecification (U). Main medical accuracy issue: Keyed answer C is defensible, but rationale's claim of lanreotide preference 'due to consistent dosing' is minor inaccuracy—guidelines (e.g., NCCN) treat octreotide and lanreotide as interchangeable for pNETs without strong preference; CLARINET supports lanreotide, PROMID octreotide, but no definitive superiority. Item is clinically sensible but misses nuance on SSA equivalence. Minimal fix: Add stem detail like 'patient prefers self-administration' to favor lanreotide's subcutaneous route over octreotide's intramuscular, making C uniquely best.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict: Not uniquely determinable. Key stem clues: 58-year-old woman with 4 cm pancreatic tail tumor, necrolytic migratory erythema, 30 lb weight loss, new-onset diabetes, biopsy-confirmed glucagonoma (Ki-67 8%), diffuse hepatic metastases, serum glucagon 2,500 pg/mL—indicating symptomatic metastatic well-differentiated pancreatic neuroendocrine tumor (glucagonoma). These drive first-line therapy as somatostatin analogs (SSAs) for symptom control and antiproliferative effects per NCCN/ENETS guidelines, ruling out surgery (A) due to metastases, everolimus combo (D) as second-line, and chemotherapy (E) for progression. Main logical issue: Stem supports SSAs but lacks discriminating details (e.g., administration preference) to choose uniquely between equivalent options B (octreotide LAR) and C (lanreotide); both are defensible first-line SSAs, leading to multiple answers (M) from underspecification (U). Main medical accuracy issue: Keyed answer C is defensible, but rationale's claim of lanreotide preference 'due to consistent dosing' is minor inaccuracy—guidelines (e.g., NCCN) treat octreotide and lanreotide as interchangeable for pNETs without strong preference; CLARINET supports lanreotide, PROMID octreotide, but no definitive superiority. Item is clinically sensible but misses nuance on SSA equivalence. Minimal fix: Add stem detail like 'patient prefers self-administration' to favor lanreotide's subcutaneous route over octreotide's intramuscular, making C uniquely best.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-014", "question": "A 35-year-old woman has chronic iron deficiency anemia requiring IV iron every 3 months, recurrent episodes of partial small bowel obstruction, and capsule endoscopy shows 5 short ulcerated strictures in the proximal jejunum. Biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions. What is the diagnosis and treatment?", "options": ["A) Crohn's disease: start infliximab", "B) NSAID enteropathy: stop all NSAIDs", "C) Cryptogenic multifocal ulcerous stenosing enteritis: budesonide 9 mg daily", "D) Small bowel lymphoma: R-CHOP chemotherapy", "E) Refractory celiac disease: cladribine"], "answer": "C", "answer_index": 2, "explanation": "Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) is characterized by multiple short ulcerated strictures without transmural inflammation. Diagnosis requires exclusion of Crohn's disease and NSAID injury. Budesonide induces remission; anti-TNF agents are ineffective. Capsule retention risk requires patency assessment.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 35-year-old woman with chronic iron deficiency anemia requiring IV iron every 3 months, recurrent partial small bowel obstruction, capsule endoscopy revealing 5 short ulcerated strictures in proximal jejunum, and biopsy showing superficial ulceration without granulomas, crypt distortion, or viral inclusions. These findings point to a rare steroid-responsive enteritis without transmural inflammation or systemic features, fitting CMUSE, while excluding Crohn's (no granulomas/crypt distortion), celiac (no crypt distortion), lymphoma (no malignancy), and NSAID enteropathy (no NSAID history mentioned, making it undefensible). Main logical issue(s), if any: None; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification, as absence of NSAID use history precludes B, and biopsy rules out others. Main medical accuracy issue(s), if any: None; CMUSE diagnosis and budesonide treatment align with current literature as a diagnosis of exclusion responsive to steroids, with anti-TNF inefficacy noted accurately in rationale. Minimal fix: No fix needed, though adding 'no history of NSAID use' to the stem would explicitly strengthen exclusion of B without altering intent.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 35-year-old woman with chronic iron deficiency anemia requiring IV iron every 3 months, recurrent partial small bowel obstruction, capsule endoscopy revealing 5 short ulcerated strictures in proximal jejunum, and biopsy showing superficial ulceration without granulomas, crypt distortion, or viral inclusions. These findings point to a rare steroid-responsive enteritis without transmural inflammation or systemic features, fitting CMUSE, while excluding Crohn's (no granulomas/crypt distortion), celiac (no crypt distortion), lymphoma (no malignancy), and NSAID enteropathy (no NSAID history mentioned, making it undefensible). Main logical issue(s), if any: None; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification, as absence of NSAID use history precludes B, and biopsy rules out others. Main medical accuracy issue(s), if any: None; CMUSE diagnosis and budesonide treatment align with current literature as a diagnosis of exclusion responsive to steroids, with anti-TNF inefficacy noted accurately in rationale. Minimal fix: No fix needed, though adding 'no history of NSAID use' to the stem would explicitly strengthen exclusion of B without altering intent.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-015", "question": "A 45-year-old HIV-positive man on tenofovir DF/emtricitabine for 10 years presents with proximal muscle weakness, bone pain, and hypophosphatemia of 1.8 mg/dL. Urine studies show phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis. What is the optimal electrolyte replacement regimen?", "options": ["A) Oral sodium phosphate 1 g TID alone", "B) Oral sodium phosphate plus calcitriol 0.25 mcg daily", "C) IV sodium phosphate 0.16 mmol/kg bolus then oral phosphate", "D) Oral sodium phosphate plus sodium bicarbonate 650 mg TID", "E) Stop tenofovir only"], "answer": "D", "answer_index": 3, "explanation": "Tenofovir-induced Fanconi syndrome causes proximal tubular loss of phosphate, glucose, and bicarbonate. Replacement requires both phosphate and bicarbonate to correct metabolic acidosis and prevent osteomalacia. Calcitriol is unnecessary if 25-OH vitamin D is normal; stopping tenofovir is necessary but insufficient for severe deficiency.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Long-term tenofovir use in HIV-positive patient, proximal muscle weakness, bone pain, hypophosphatemia (1.8 mg/dL), phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis, pointing to tenofovir-induced Fanconi syndrome with phosphate and bicarbonate wasting. These findings necessitate electrolyte replacement targeting both losses for optimal management. Main logical issue(s): None; the stem provides sufficient details to discriminate options without contradictions or underspecification, as the question focuses specifically on electrolyte replacement, making D uniquely defensible. Main medical accuracy issue(s): None; aligns with standard care for Fanconi syndrome, where phosphate and bicarbonate supplementation corrects hypophosphatemia and acidosis, respectively, while stopping tenofovir is implied but separate from replacement. The rationale accurately notes calcitriol's conditional use, consistent with guidelines (e.g., unnecessary if vitamin D normal, though not specified, but irrelevant to electrolyte focus). Minimal fix: Add 'after discontinuing tenofovir' to the stem to explicitly address causality, enhancing clarity without altering intent.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Long-term tenofovir use in HIV-positive patient, proximal muscle weakness, bone pain, hypophosphatemia (1.8 mg/dL), phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis, pointing to tenofovir-induced Fanconi syndrome with phosphate and bicarbonate wasting. These findings necessitate electrolyte replacement targeting both losses for optimal management. Main logical issue(s): None; the stem provides sufficient details to discriminate options without contradictions or underspecification, as the question focuses specifically on electrolyte replacement, making D uniquely defensible. Main medical accuracy issue(s): None; aligns with standard care for Fanconi syndrome, where phosphate and bicarbonate supplementation corrects hypophosphatemia and acidosis, respectively, while stopping tenofovir is implied but separate from replacement. The rationale accurately notes calcitriol's conditional use, consistent with guidelines (e.g., unnecessary if vitamin D normal, though not specified, but irrelevant to electrolyte focus). Minimal fix: Add 'after discontinuing tenofovir' to the stem to explicitly address causality, enhancing clarity without altering intent.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-016", "question": "A 70-year-old man with coronary artery disease is found to have clonal hematopoiesis of indeterminate potential (CHIP) with JAK2 V617F mutation at variant allele frequency of 12% on peripheral blood NGS. CBC is normal and there is no splenomegaly. What is his annual risk of thrombosis and recommended prophylaxis?", "options": ["A) 1% annual thrombosis risk; no prophylaxis needed", "B) 5% annual thrombosis risk; start hydroxyurea", "C) 0.5% annual thrombosis risk; start low-dose aspirin", "D) 10% annual thrombosis risk; start therapeutic enoxaparin", "E) No increased thrombosis risk; no prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "CHIP with JAK2 V617F confers a 0.5-1% annual risk of thrombosis independent of traditional risk factors. Low-dose aspirin is recommended for primary prophylaxis. Progression to myelofibrosis or AML is rare (<1% annually). Hydroxyurea is not indicated without overt myeloproliferative neoplasm.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 70-year-old with CAD, CHIP with JAK2 V617F at 12% VAF, normal CBC, no splenomegaly—these indicate asymptomatic clonal hematopoiesis without overt MPN, but with mutation-specific thrombosis risk warranting prophylaxis. The question asks for annual thrombosis risk and recommended prophylaxis, implying the mutation-associated risk (0.5-1% annually) and aspirin for primary prevention, as per emerging data on JAK2 CHIP. Main logical issue(s): None; stem provides sufficient details to discriminate options without contradictions or underspecification, supporting C as uniquely best (low risk but prophylaxis indicated). Alternatives: A underestimates prophylaxis need; B overestimates risk and misapplies hydroxyurea (for MPN); D grossly overestimates risk and uses anticoagulation inappropriately; E denies increased risk. Main medical accuracy issue(s): Mostly consistent with current literature (e.g., JAK2 CHIP confers ~0.5-1% annual thrombosis risk, aspirin often recommended), though exact risk estimates vary slightly by study and aspirin isn't universally guideline-mandated yet—still board-relevant. Minimal fix: None needed; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 70-year-old with CAD, CHIP with JAK2 V617F at 12% VAF, normal CBC, no splenomegaly—these indicate asymptomatic clonal hematopoiesis without overt MPN, but with mutation-specific thrombosis risk warranting prophylaxis. The question asks for annual thrombosis risk and recommended prophylaxis, implying the mutation-associated risk (0.5-1% annually) and aspirin for primary prevention, as per emerging data on JAK2 CHIP. Main logical issue(s): None; stem provides sufficient details to discriminate options without contradictions or underspecification, supporting C as uniquely best (low risk but prophylaxis indicated). Alternatives: A underestimates prophylaxis need; B overestimates risk and misapplies hydroxyurea (for MPN); D grossly overestimates risk and uses anticoagulation inappropriately; E denies increased risk. Main medical accuracy issue(s): Mostly consistent with current literature (e.g., JAK2 CHIP confers ~0.5-1% annual thrombosis risk, aspirin often recommended), though exact risk estimates vary slightly by study and aspirin isn't universally guideline-mandated yet—still board-relevant. Minimal fix: None needed; item is unambiguous and accurate as is.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-017", "question": "A 22-year-old man has recurrent sinopulmonary infections with Streptococcus pneumoniae, systemic lupus erythematosus-like malar rash, and low C1q level of 5 mg/dL (normal 10-25) with normal C1r and C1s. Genetic testing shows homozygous C1QA c.150C>G mutation. What is the recommended infection prophylaxis?", "options": ["A) Penicillin V 250 mg BID lifelong", "B) IVIG 400 mg/kg monthly", "C) No prophylaxis needed", "D) Posaconazole 300 mg daily", "E) Pneumococcal vaccine only"], "answer": "A", "answer_index": 0, "explanation": "C1q deficiency causes impaired classical pathway opsonization of encapsulated organisms and SLE-like autoimmunity. Lifelong penicillin prophylaxis is recommended to prevent invasive pneumococcal disease. IVIG is not indicated unless specific antibody deficiency coexists; fungal prophylaxis is unnecessary.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent sinopulmonary infections with Streptococcus pneumoniae, SLE-like malar rash, isolated low C1q level (5 mg/dL, normal 10-25) with normal C1r and C1s, and homozygous C1QA c.150C>G mutation confirming C1q deficiency. These point to impaired classical complement pathway opsonization, increasing susceptibility to encapsulated bacteria like pneumococcus, necessitating prophylaxis. Main logical issue(s): None; the vignette provides sufficient details to discriminate options without contradictions or underspecification, supporting A as uniquely best. Option B (IVIG) is inferior without evidence of antibody deficiency; C (none) ignores recurrent infections; D (posaconazole) targets fungi irrelevantly; E (vaccine only) is inadequate for high-risk recurrence. Main medical accuracy issue(s): None; aligns with consensus on C1q deficiency management, where lifelong penicillin prophylaxis prevents invasive pneumococcal disease in patients with recurrent infections, per immunology guidelines (e.g., AAAAI, ESID). IVIG is not standard absent hypogammaglobulinemia; fungal risks are not prominent. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent sinopulmonary infections with Streptococcus pneumoniae, SLE-like malar rash, isolated low C1q level (5 mg/dL, normal 10-25) with normal C1r and C1s, and homozygous C1QA c.150C>G mutation confirming C1q deficiency. These point to impaired classical complement pathway opsonization, increasing susceptibility to encapsulated bacteria like pneumococcus, necessitating prophylaxis. Main logical issue(s): None; the vignette provides sufficient details to discriminate options without contradictions or underspecification, supporting A as uniquely best. Option B (IVIG) is inferior without evidence of antibody deficiency; C (none) ignores recurrent infections; D (posaconazole) targets fungi irrelevantly; E (vaccine only) is inadequate for high-risk recurrence. Main medical accuracy issue(s): None; aligns with consensus on C1q deficiency management, where lifelong penicillin prophylaxis prevents invasive pneumococcal disease in patients with recurrent infections, per immunology guidelines (e.g., AAAAI, ESID). IVIG is not standard absent hypogammaglobulinemia; fungal risks are not prominent. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-018", "question": "A 68-year-old man on deferoxamine for transfusional iron overload (ferritin 3,500 ng/mL) develops a cavitary right upper lobe lung lesion. Biopsy shows broad nonseptate hyphae with right-angle branching. What is the optimal antifungal combination therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone", "B) Amphotericin B plus posaconazole 300 mg daily", "C) Isavuconazole 372 mg daily", "D) Amphotericin B plus deferasirox 20 mg/kg daily", "E) Caspofungin 50 mg daily plus posaconazole"], "answer": "D", "answer_index": 3, "explanation": "Deferoxamine is a siderophore that enhances mucoraceal growth and must be stopped. Deferasirox has intrinsic antifungal activity against Mucorales. Liposomal amphotericin B is first-line; combination with deferasirox improves outcomes. Isavuconazole is second-line monotherapy; caspofungin has minimal activity.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K\\nVerdict on keyed answer: Miskeyed\\nKey stem clues that drive (or fail to drive) a unique best answer: Patient on deferoxamine for transfusional iron overload (ferritin 3,500 ng/mL), cavitary right upper lobe lesion, biopsy showing broad nonseptate hyphae with right-angle branching, indicating mucormycosis; question specifies 'optimal antifungal combination therapy,' excluding monotherapies A and C.\\nMain logical issue(s), if any: No internal contradictions; options allow discrimination among combinations (B, D, E); a unique best answer exists (B, as amphotericin B plus posaconazole has supportive evidence for refractory mucormycosis), but the key (D) does not match it, fitting miskeyed definition.\\nMain medical accuracy issue(s), if any: Keyed answer D and rationale promote amphotericin B plus deferasirox as improving outcomes, but this contradicts mainstream guidelines and the DEFEAT Mucor trial showing higher mortality with deferasirox in mucormycosis; deferoxamine should be stopped, but deferasirox lacks proven benefit and may harm; isavuconazole (C) is acceptable monotherapy, not second-line only; caspofungin indeed has minimal activity.\\nMinimal fix: Change the keyed answer to B (amphotericin B plus posaconazole), which aligns with evidence for combination in select cases without promoting harmful therapy.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K\nVerdict on keyed answer: Miskeyed\nKey stem clues that drive (or fail to drive) a unique best answer: Patient on deferoxamine for transfusional iron overload (ferritin 3,500 ng/mL), cavitary right upper lobe lesion, biopsy showing broad nonseptate hyphae with right-angle branching, indicating mucormycosis; question specifies 'optimal antifungal combination therapy,' excluding monotherapies A and C.\nMain logical issue(s), if any: No internal contradictions; options allow discrimination among combinations (B, D, E); a unique best answer exists (B, as amphotericin B plus posaconazole has supportive evidence for refractory mucormycosis), but the key (D) does not match it, fitting miskeyed definition.\nMain medical accuracy issue(s), if any: Keyed answer D and rationale promote amphotericin B plus deferasirox as improving outcomes, but this contradicts mainstream guidelines and the DEFEAT Mucor trial showing higher mortality with deferasirox in mucormycosis; deferoxamine should be stopped, but deferasirox lacks proven benefit and may harm; isavuconazole (C) is acceptable monotherapy, not second-line only; caspofungin indeed has minimal activity.\nMinimal fix: Change the keyed answer to B (amphotericin B plus posaconazole), which aligns with evidence for combination in select cases without promoting harmful therapy.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-019", "question": "A 62-year-old woman with high-grade serous ovarian cancer develops subacute cerebellar ataxia, dysarthria, and nystagmus over 3 weeks. Anti-Yo antibodies are positive at titer 1:10,240 in serum and CSF. CSF shows lymphocytic pleocytosis (50 cells/μL). What is the immunotherapy protocol?", "options": ["A) Methylprednisolone 1 g IV x3 days then prednisone 1 mg/kg", "B) IVIG 2 g/kg monthly", "C) Cyclophosphamide 750 mg/m2 monthly plus prednisone", "D) Rituximab 375 mg/m2 weekly x4 plus prednisone", "E) Tumor debulking surgery only"], "answer": "C", "answer_index": 2, "explanation": "Anti-Yo associated paraneoplastic cerebellar degeneration is B-cell mediated; cyclophosphamide crosses the blood-brain barrier and depletes plasma cells more effectively than rituximab. Combined with steroids, it stabilizes neurologic decline. IVIG is less effective for anti-Yo; tumor treatment alone is insufficient.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 62-year-old woman with high-grade serous ovarian cancer, subacute onset of cerebellar ataxia, dysarthria, nystagmus over 3 weeks, positive anti-Yo antibodies at high titer in serum/CSF, CSF lymphocytic pleocytosis (50 cells/μL)—classic for anti-Yo paraneoplastic cerebellar degeneration (PCD). These drive selection of immunotherapy targeting immune response beyond tumor treatment. Main logical issue(s): none; stem supports unique best answer via discriminating findings implying need for aggressive immunosuppression effective against plasma cells in PCD. Main medical accuracy issue(s): Rationale describes as 'B-cell mediated,' which is partially accurate but oversimplifies; anti-Yo PCD primarily involves T-cell cytotoxicity against intracellular antigens, though humoral components exist—treatment with cyclophosphamide (alkylating agent depleting B/plasma cells, crossing BBB) plus steroids aligns with guidelines for stabilization. Minimal fix: None required. Stepwise: a) Question asks for optimal immunotherapy for anti-Yo PCD. b) Discriminating findings: cancer association, subacute cerebellar syndrome, high anti-Yo titer, CSF inflammation. c) Implies PCD requiring immunosuppression + tumor Rx. d) Keyed C fits: cyclophosphamide + prednisone stabilizes decline per evidence. e) A worse: steroids alone often insufficient; B: IVIG less effective for anti-Yo; D: rituximab depletes B-cells but not plasma cells as well; E: surgery insufficient without immunotherapy.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 62-year-old woman with high-grade serous ovarian cancer, subacute onset of cerebellar ataxia, dysarthria, nystagmus over 3 weeks, positive anti-Yo antibodies at high titer in serum/CSF, CSF lymphocytic pleocytosis (50 cells/μL)—classic for anti-Yo paraneoplastic cerebellar degeneration (PCD). These drive selection of immunotherapy targeting immune response beyond tumor treatment. Main logical issue(s): none; stem supports unique best answer via discriminating findings implying need for aggressive immunosuppression effective against plasma cells in PCD. Main medical accuracy issue(s): Rationale describes as 'B-cell mediated,' which is partially accurate but oversimplifies; anti-Yo PCD primarily involves T-cell cytotoxicity against intracellular antigens, though humoral components exist—treatment with cyclophosphamide (alkylating agent depleting B/plasma cells, crossing BBB) plus steroids aligns with guidelines for stabilization. Minimal fix: None required. Stepwise: a) Question asks for optimal immunotherapy for anti-Yo PCD. b) Discriminating findings: cancer association, subacute cerebellar syndrome, high anti-Yo titer, CSF inflammation. c) Implies PCD requiring immunosuppression + tumor Rx. d) Keyed C fits: cyclophosphamide + prednisone stabilizes decline per evidence. e) A worse: steroids alone often insufficient; B: IVIG less effective for anti-Yo; D: rituximab depletes B-cells but not plasma cells as well; E: surgery insufficient without immunotherapy.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-020", "question": "A 35-year-old man develops fever, facial edema, diffuse erythematous rash covering 60% BSA, eosinophilia of 2,200/μL, and atypical lymphocytes 3 weeks after starting allopurinol 300 mg daily for gout. AST is 850 U/L and ALT is 620 U/L. What is the appropriate corticosteroid regimen?", "options": ["A) Prednisone 1 mg/kg PO daily, taper over 2 weeks", "B) Methylprednisolone 1-2 mg/kg IV, slow taper over 8-12 weeks", "C) Methylprednisolone 1 g IV x3 days only", "D) No steroids; antihistamines and topical therapy", "E) Topical triamcinolone 0.1% BSA"], "answer": "B", "answer_index": 1, "explanation": "DRESS syndrome with hepatitis requires high-dose systemic steroids; rapid taper risks relapse and rebound hepatitis. Slow taper over 8-12 weeks with monitoring for viral reactivation (HHV-6) is standard. Pulse therapy alone is insufficient; antihistamines are adjunctive only.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include fever, facial edema, diffuse rash covering 60% BSA, eosinophilia (2,200/μL), atypical lymphocytes, and transaminitis (AST 850 U/L, ALT 620 U/L) occurring 3 weeks after starting allopurinol, classic for DRESS syndrome with hepatic involvement. These findings imply severe systemic hypersensitivity requiring aggressive systemic corticosteroid therapy with prolonged taper to prevent relapse and rebound organ damage. No main logical issues; the vignette is coherent, supports a single best answer (B) without contradictions or underspecification, as options are discriminable based on severity, route, and duration. No main medical accuracy issues; keyed answer aligns with current guidelines (e.g., high-dose IV methylprednisolone 1-2 mg/kg followed by slow taper over 8-12 weeks for severe DRESS with organ involvement, monitoring for viral reactivation like HHV-6). Alternatives are appropriately inferior: A risks relapse with rapid taper; C provides insufficient duration; D omits necessary systemic therapy; E is inadequate for systemic disease. Minimal fix: No fix needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include fever, facial edema, diffuse rash covering 60% BSA, eosinophilia (2,200/μL), atypical lymphocytes, and transaminitis (AST 850 U/L, ALT 620 U/L) occurring 3 weeks after starting allopurinol, classic for DRESS syndrome with hepatic involvement. These findings imply severe systemic hypersensitivity requiring aggressive systemic corticosteroid therapy with prolonged taper to prevent relapse and rebound organ damage. No main logical issues; the vignette is coherent, supports a single best answer (B) without contradictions or underspecification, as options are discriminable based on severity, route, and duration. No main medical accuracy issues; keyed answer aligns with current guidelines (e.g., high-dose IV methylprednisolone 1-2 mg/kg followed by slow taper over 8-12 weeks for severe DRESS with organ involvement, monitoring for viral reactivation like HHV-6). Alternatives are appropriately inferior: A risks relapse with rapid taper; C provides insufficient duration; D omits necessary systemic therapy; E is inadequate for systemic disease. Minimal fix: No fix needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]